We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Oxford Expression Technologies (OET) and Eden Biodesign have announced that they have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing and analytical development services. In return, Eden Biodesign’s customers will have access to OET’s wide range of baculovirus capabilities to meet their individual protein expression requirements. OET customers will benefit from a smooth transition between optimization of expression and cGMP production and scale-up and the ability to transfer projects intended for clinical development to Eden Biodesign’s process development, cGMP manufacturing and analytical development services offered from their EMEA inspected facilities located in Liverpool, UK. Eden Biodesign’s customers will be able to take advantage of OET's experience in troubleshooting baculovirus expression; the use of flashback™ technology to increase protein yield in difficult to express proteins; and the development of a protocol for optimal expression of their proteins. Commenting on the alliance, Crawford Brown, CEO of Eden Biodesign, said: “Baculovirus protein expression technology can enable faster, easier and more cost-effective protein production compared with other expression methods. By collaborating with OET, a world leader in the baculovirus field, we can help the increasing number of biotechnology and pharmaceutical companies who are interested in evaluating the performance of their biotherapeutic and vaccine products using this exciting technology to progress rapidly into and through clinical development.”